PASADENA, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW) ("LIXTE" or the "Company"), today announced the dosing of the first patient in a new clinical trial in collaboration with the Netherlands Cancer Institute (NKI) and supported by F. Hoffmann-La Roche Ltd. ("Roche") for treatment of unresponsive (MSI Low) metastatic colorectal cancer. As part of the clinical trial (NCT06012734, clinicaltrials.gov), LIXTE is providing its lead compound, LB-100, and R ...

Roche Holding AG (RHHBY) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices - - has triggered this rating change. The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate. Since a changing ...

Roche is committed to supporting all those working to overcome the mpox outbreak by providing access to high-quality Polymerase Chain Reaction (PCR) testing Roche confirms that its cobas MPXV test, as well as the LightMix® research use only kits, detect the latest mpox virus variants It is actively working to enhance laboratory testing capacity for mpox worldwide Basel, 20 August 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it is supporting the international response to the mpox global hea ...

Core Viewpoint - Veteran investor David Roche predicts a bear market in 2025 driven by smaller-than-expected rate cuts, a slowing U.S. economy, and an artificial intelligence bubble [1][2][3] Group 1: Federal Reserve and Interest Rates - Roche expects the Federal Reserve to resist reducing rates to the market's desired level of 3.50%, with the Fed's median forecast for 2025 at 4.1% [2] - Market participants anticipate rates below 4.1% by September 2025, according to the CME FedWatch Tool [2] Group 2: Economic Growth and Corporate Profits - Roche warns that corporate profits will not meet expectations due to a slowing economy [2] - The anticipated economic slowdown is expected to contribute to a bear market [3] Group 3: Artificial Intelligence Sector - The AI sector is viewed as having "entered bubble terrain decisively," which is expected to contribute to slower economic growth [3] - Roche predicts that the AI bubble will exit its current state over the next six months, further impacting the economy [3] Group 4: Market Predictions - Roche forecasts a bear market of approximately minus 20% in 2025, potentially starting at the end of 2024 [3] - This prediction does not take into account the outcome of the U.S. Presidential election in November [3]

Approval is based on data from two Phase III studies in branch and central retinal vein occlusion (RVO) showing early and sustained vision improvements non-inferior to aflibercept, and robust retinal drying with Vabysmo Additional submitted data shows that up to 60% of people receiving Vabysmo were able to extend treatment intervals to three or four months Vabysmo is already approved in several countries, including the US and Japan, for RVO and in nearly 100 countries for people with nAMD and DME RVO is the ...

"We are fast-tracking the clinical development of our obesity portfolio with the aim to bring these medications to patients faster than anticipated. We will communicate updated timelines when appropriate," a Roche spokesperson told FOX Business. HIMS & HERS ROLLS OUT WEIGHT-LOSS SHOTS MUCH CHEAPER THAN OZEMPIC, WEGOVY GLP-1 agonists are a class of Type 2 diabetes drugs that improve blood sugar control but may also lead to weight loss. Semaglutide, which is the active ingredient in Novo Nordisk's Wegovy and ...

Swiss pharmaceutical giant Roche said Monday it is accelerating the development of its Wegovy rival weight loss drugs following promising early stage trial data. The company's two obesity drug candidates are progressing to the next phase of trials and could come to market within the next few years, providing a potential pill-based alternative to Novo Nordisk's Wegovy and Eli Lilly's Zepbound weight loss injections. "We are fast-tracking the clinical development of our obesity portfolio with the aim to bring ...

Roche's latest breakthrough could be a game changer, but it's still too early to say. That's just what happened after an announcement by Roche Holding (RHHBY 3.03%) on July 16. Shares of Novo Nordisk (NVO -0.88%), Eli Lilly (LLY -2.02%), Structure Therapeutics, Altimmune, and Viking Therapeutics all took a hit. Biotechs with clinical-stage weight loss candidates, specifically Viking and Altimmune, fell by nearly 13%, with larger players dropping by more than 4% even while the market was mostly flat. The mar ...

Basel, 29 July 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the completion of the acquisition of LumiraDx's Point of Care technology, following the receipt of all required antitrust and regulatory clearances. Roche will now embark on the full integration of the company's innovative multi-assay point of care platform and the related R&D, operational and commercial sites into its global organisation. "Access to diagnostic testing is critical for the delivery of healthcare worldwide and we are con ...

Roche HY 2024 results Thomas Schinecker Chief Executive Officer HY 2024: Strong business performance in both divisions • Diagnostics regulatory: cobas c703 and ISE neo (EU), cobas Liat Respiratory Panel FDA EUA, cobas pro serology solution (FDA), Accu-Chek SmartGuide CGM (EU), VENTANA Kappa Lambda Dual ISH mRNA Probe Cocktail (EU), HPV self-collection solution (FDA) • Pivotal readouts: Ph III (REGENCY) Gazyva in LN and Ph III (SKYSCRAPER-01) tiragolumab in 1L NSCLC Roche Any statements regarding earnings pe ...